This Week in 340B: October 28 – November 3, 2025

The approval of rebate models for eight drug manufacturers in the 340B program and the ongoing litigation updates have significant implications for drug pricing strategies, market access, and compliance for pharmaceutical companies. Biotech/pharma professionals need to monitor these developments closely to adapt their pricing and distribution strategies accordingly.